bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 1 from Impact of Prior Bevacizumab Treatment on VEGF-A and PlGF Levels and Outcome Following Second-Line Aflibercept Treatment: Biomarker Post Hoc Analysis of the VELOUR Trial
Authors: Van Cutsem Eric , Paccard Caroline , Chiron Marielle , Tabernero Josep
Published: April 2023

Supp Figure 1. Longitudinal analysis of (A) VEGF-A and (B) PlGF.
Supplementary Data from Current Panorama and Challenges for Neoadjuvant Cancer Immunotherapy
Authors: Benitez Jose Carlos , Remon Jordi , Besse Benjamin
Published: April 2023

Supplementary Table S1: Randomized phase III clinical trials with ICI in the adjuvant setting in different solid tumors
Supplementary Table 1 from Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration-resistant Prostate Cancer
Authors: Agarwal Neeraj , Nussenzveig Roberto , Hahn Andrew W. , Hoffman John M. , Morton Kathryn , Gupta Sumati , Batten Julia , Thorley Jared , Hawks Josiah , Santos Victor Sacristan , Nachaegari Gayatri , Wang Xuechen , Boucher Kenneth , Haaland Benjamin , Maughan Benjamin L.
Published: April 2023

Interim analysis of Grade {greater than or equal to}3 hematologic toxicity in the first 10 patients recruited to the combination arm (radium-223 + enzalutamide).
Supplementary Figure 1 from A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer
Authors: Aggarwal Rahul R. , Schweizer Michael T. , Nanus David M. , Pantuck Allan J. , Heath Elisabeth I. , Campeau Eric , Attwell Sarah , Norek Karen , Snyder Margo , Bauman Lisa , Lakhotia Sanjay , Feng Felix Y. , Small Eric J. , Abida Wassim , Alumkal Joshi J.
Published: April 2023

Supplementary Figure 1
Supplementary Data from Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non–Small Cell Lung Cancer
Authors: Ricciuti Biagio , Recondo Gonzalo , Spurr Liam F. , Li Yvonne Y. , Lamberti Giuseppe , Venkatraman Deepti , Umeton Renato , Cherniack Andrew D. , Nishino Mizuki , Sholl Lynette M. , Shapiro Geoffrey I. , Awad Mark M. , Cheng Michael L.
Published: April 2023

Supplementary Material
Supplementary Data from A Prospective Trial of 68Ga-PSMA and 18F-FDG PET/CT in Nonmetastatic Prostate Cancer Patients with an Early PSA Progression During Castration
Authors: Wang Beihe , Liu Chang , Wei Yu , Meng Jin , Zhang Yingjian , Gan Hualei , Xu Xiaoping , Wan Fangning , Pan Jian , Ma Xuejun , Hu Silong , Freedland Stephen J. , Song Shaoli , Ye DingWei , Zhu Yao
Published: April 2023

Supplementary methods, tables and figures.
Table and Fig from Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study
Authors: Vu Khoan , Wu Chi-Heng , Yang Chen-Yen , Zhan Aaron , Cavallone Erika , Berry Wade , Heeter Pamela , Pincus Laura , Wieduwilt Matthew J. , William Basem M. , Andreadis Charalambos , Kaplan Lawrence K. , McCormick Frank , Porcu Pierluigi , Brammer Jonathan E. , Ai Weiyun Z.
Published: April 2023

Table S1, S2, S3, S4 Fig. S1, S2
Supplementary Legend from CD8+ T-cell–Mediated Immunoediting Influences Genomic Evolution and Immune Evasion in Murine Gliomas
Authors: Kane Joshua R. , Zhao Junfei , Tsujiuchi Takashi , Laffleur Brice , Arrieta Víctor A. , Mahajan Aayushi , Rao Ganesh , Mela Angeliki , Dmello Crismita , Chen Li , Zhang Daniel Y. , González-Buendia Edgar , Lee-Chang Catalina , Xiao Ting , Rothschild Gerson , Basu Uttiya , Horbinski Craig , Lesniak Maciej S. , Heimberger Amy B. , Rabadan Raul , Canoll Peter , Sonabend Adam M.
Published: April 2023

Supplementary Legend
Figure S2 from CD8+ T-cell–Mediated Immunoediting Influences Genomic Evolution and Immune Evasion in Murine Gliomas
Authors: Kane Joshua R. , Zhao Junfei , Tsujiuchi Takashi , Laffleur Brice , Arrieta Víctor A. , Mahajan Aayushi , Rao Ganesh , Mela Angeliki , Dmello Crismita , Chen Li , Zhang Daniel Y. , González-Buendia Edgar , Lee-Chang Catalina , Xiao Ting , Rothschild Gerson , Basu Uttiya , Horbinski Craig , Lesniak Maciej S. , Heimberger Amy B. , Rabadan Raul , Canoll Peter , Sonabend Adam M.
Published: April 2023

Expression of upstream activators of the MAPK pathway correlates with functional activation of the ERK and p38 cascades. (A) Correlation between Braf expression and pERK in tumors from mice treated with anti-CD8+ (n=8) and isotype control (n=8) antibodies. (B) Correlation between Ptpn11 expression and pERK in tumors from mice treated with anti-CD8 (n=8) and isotype control (n=8) antibodies. (C) Correlation between Nras expression and pERK in tumors from mice treated with anti-CD8 (n=8) and isotype control (n=8) antibodies. (D) Correlation between Traf6 expression and p-p38 in tumors from mice treated with anti-CD8+ (n=8) and isotype control (n=8) antibodies. r and p values by Pearson correlation coefficient. Points represent individual mice.
Figure S1 from CD8+ T-cell–Mediated Immunoediting Influences Genomic Evolution and Immune Evasion in Murine Gliomas
Authors: Kane Joshua R. , Zhao Junfei , Tsujiuchi Takashi , Laffleur Brice , Arrieta Víctor A. , Mahajan Aayushi , Rao Ganesh , Mela Angeliki , Dmello Crismita , Chen Li , Zhang Daniel Y. , González-Buendia Edgar , Lee-Chang Catalina , Xiao Ting , Rothschild Gerson , Basu Uttiya , Horbinski Craig , Lesniak Maciej S. , Heimberger Amy B. , Rabadan Raul , Canoll Peter , Sonabend Adam M.
Published: April 2023

Transgenic murine glioma model possesses increased CD4+ and CD8+ T-cell infiltration early in tumor development. (A) Representative bioluminescence activity of tumor captured 21 and 35 days post-tumor induction (left). Scatter plot showing an example of an ex vivo flow cytometry of the brain tumors using the CD4+ and CD8+ markers (right). (B) Bioluminescence was measured at seven time points between 21 and 63 days post-tumor induction (n=8/time point). (C) Kaplan-Meier survival curve illustrating the time points of flow cytometric analysis relative to initiation of tumor-related death (n=16). (D) Bar plots showing CD4+ (left) and CD8+ (right) T-cell tumor infiltration normalized against the contralateral brain hemisphere, and bioluminescence signal at 21 and at 35 days post-tumor induction (n=16). Data in (D) is shown as mean {plus minus} SEM. p= 0.0189 and p= 0.026 by unpaired studentÂ's t-test.
Supplemental Table 4 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma
Authors: Postow Michael A. , Knox Susan J. , Goldman Debra A. , Elhanati Yuval , Mavinkurve Vikram , Wong Phillip , Halpenny Darragh , Reddy Sunil K. , Vado Kenya , McCabe Danielle , Ramirez Kristen Aufiero , Macri Mary , Schwarzenberger Paul , Ricciardi Toni , Ryan Aileen , Venhaus Ralph , Momtaz Parisa , Shoushtari Alexander N. , Callahan Margaret K. , Chapman Paul B. , Wolchok Jedd D. , Subrahmanyam Priyanka B. , Maecker Holden T. , Panageas Katherine S. , Barker Christopher A.
Published: April 2023

TEAE (grade {greater than or equal to}2 events or grade 1 events occurring in {greater than or equal to}2 patients)
Supplemental Table 3 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma
Authors: Postow Michael A. , Knox Susan J. , Goldman Debra A. , Elhanati Yuval , Mavinkurve Vikram , Wong Phillip , Halpenny Darragh , Reddy Sunil K. , Vado Kenya , McCabe Danielle , Ramirez Kristen Aufiero , Macri Mary , Schwarzenberger Paul , Ricciardi Toni , Ryan Aileen , Venhaus Ralph , Momtaz Parisa , Shoushtari Alexander N. , Callahan Margaret K. , Chapman Paul B. , Wolchok Jedd D. , Subrahmanyam Priyanka B. , Maecker Holden T. , Panageas Katherine S. , Barker Christopher A.
Published: April 2023

TRAE (grade {greater than or equal to}2 events or grade 1 events occurring in {greater than or equal to}2 patients)
Table S3 from Population-based Screening for BRAFV600E in Metastatic Colorectal Cancer Reveals Increased Prevalence and Poor Prognosis
Authors: Chu Jenny E. , Johnson Benny , Kugathasan Laveniya , Morris Van K. , Raghav Kanwal , Swanson Lucas , Lim Howard J. , Renouf Daniel J. , Gill Sharlene , Wolber Robert , Karsan Aly , Kopetz Scott , Schaeffer David F. , Loree Jonathan M.
Published: April 2023

Clinical characteristics of patients with BRAFV600E mCRC receiving first-line palliative chemotherapy.
Supplemental Table 1 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma
Authors: Postow Michael A. , Knox Susan J. , Goldman Debra A. , Elhanati Yuval , Mavinkurve Vikram , Wong Phillip , Halpenny Darragh , Reddy Sunil K. , Vado Kenya , McCabe Danielle , Ramirez Kristen Aufiero , Macri Mary , Schwarzenberger Paul , Ricciardi Toni , Ryan Aileen , Venhaus Ralph , Momtaz Parisa , Shoushtari Alexander N. , Callahan Margaret K. , Chapman Paul B. , Wolchok Jedd D. , Subrahmanyam Priyanka B. , Maecker Holden T. , Panageas Katherine S. , Barker Christopher A.
Published: April 2023

Time from prior treatment to start of treatment within this protocol
Supplemental Methods from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma
Authors: Postow Michael A. , Knox Susan J. , Goldman Debra A. , Elhanati Yuval , Mavinkurve Vikram , Wong Phillip , Halpenny Darragh , Reddy Sunil K. , Vado Kenya , McCabe Danielle , Ramirez Kristen Aufiero , Macri Mary , Schwarzenberger Paul , Ricciardi Toni , Ryan Aileen , Venhaus Ralph , Momtaz Parisa , Shoushtari Alexander N. , Callahan Margaret K. , Chapman Paul B. , Wolchok Jedd D. , Subrahmanyam Priyanka B. , Maecker Holden T. , Panageas Katherine S. , Barker Christopher A.
Published: April 2023

Additional description of correlative immunologic assays
Figure S2 from Population-based Screening for BRAFV600E in Metastatic Colorectal Cancer Reveals Increased Prevalence and Poor Prognosis
Authors: Chu Jenny E. , Johnson Benny , Kugathasan Laveniya , Morris Van K. , Raghav Kanwal , Swanson Lucas , Lim Howard J. , Renouf Daniel J. , Gill Sharlene , Wolber Robert , Karsan Aly , Kopetz Scott , Schaeffer David F. , Loree Jonathan M.
Published: April 2023

Kaplan-Meier estimation of overall survival of mCRC patients with BRAFV600E mutations detected by NGS (BRAFNGS) and two IHC (BRAFIHC) subsets: patients that received any NGS testing and patients that were never NGS tested.
Supplementary Data from Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma
Authors: Perumal Deepak , Imai Naoko , Laganà Alessandro , Finnigan John , Melnekoff David , Leshchenko Violetta V. , Solovyov Alexander , Madduri Deepu , Chari Ajai , Cho Hearn Jay , Dudley Joel T. , Brody Joshua D. , Jagannath Sundar , Greenbaum Benjamin , Gnjatic Sacha , Bhardwaj Nina , Parekh Samir
Published: April 2023

Supplementary Figures and Tables
Supplementary Table S2 from Genome Instability Profiles Predict Disease Outcome in a Cohort of 4,003 Patients with Breast Cancer
Authors: Lischka Annette , Doberstein Natalie , Freitag-Wolf Sandra , Koçak Ayla , Gemoll Timo , Heselmeyer-Haddad Kerstin , Ried Thomas , Auer Gert , Habermann Jens K.
Published: April 2023

Correlation between standard clinicopathological and genome instability parameters.
Supplemental Figure 3a from Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia
Authors: Danilov Alexey V. , Herbaux Charles , Walter Harriet S. , Hillmen Peter , Rule Simon A. , Kio Ebenezer A. , Karlin Lionel , Dyer Martin J.S. , Mitra Siddhartha S. , Yi Ping Cheng , Humeniuk Rita , Huang Xi , Zhou Ziqian , Bhargava Pankaj , Jürgensmeier Juliane M. , Fegan Christopher D.
Published: April 2023

Supplemental Figure 3. Mean (SD) TIRA plasma concentration. Cycle 1 Day 8 data are shown in patients receiving TIRA monotherapy with A) TIRA/IDELA, and B) TIRA/ENTO*
Supplemental Figure 2 from Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia
Authors: Danilov Alexey V. , Herbaux Charles , Walter Harriet S. , Hillmen Peter , Rule Simon A. , Kio Ebenezer A. , Karlin Lionel , Dyer Martin J.S. , Mitra Siddhartha S. , Yi Ping Cheng , Humeniuk Rita , Huang Xi , Zhou Ziqian , Bhargava Pankaj , Jürgensmeier Juliane M. , Fegan Christopher D.
Published: April 2023

Supplemental Figure 2. Patient disposition
Supplementary Figure S4 from Genome Instability Profiles Predict Disease Outcome in a Cohort of 4,003 Patients with Breast Cancer
Authors: Lischka Annette , Doberstein Natalie , Freitag-Wolf Sandra , Koçak Ayla , Gemoll Timo , Heselmeyer-Haddad Kerstin , Ried Thomas , Auer Gert , Habermann Jens K.
Published: April 2023

Kaplan Meier curves of clinicopathological and image cytometric data.
Supplementary Figure S3 from Genome Instability Profiles Predict Disease Outcome in a Cohort of 4,003 Patients with Breast Cancer
Authors: Lischka Annette , Doberstein Natalie , Freitag-Wolf Sandra , Koçak Ayla , Gemoll Timo , Heselmeyer-Haddad Kerstin , Ried Thomas , Auer Gert , Habermann Jens K.
Published: April 2023

Univariable Cox regressions, disease-specific survival.
Supplementary Materials from Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy
Authors: Huarte Eduardo , O'Connor Roddy S. , Peel Michael T. , Nunez-Cruz Selene , Leferovich John , Juvekar Ashish , Yang Yan-ou , Truong Lisa , Huang Taisheng , Naim Ahmad , Milone Michael C. , Smith Paul A.
Published: April 2023

Huate et al supplemental figures.
Supplementary Figure S2 from Genome Instability Profiles Predict Disease Outcome in a Cohort of 4,003 Patients with Breast Cancer
Authors: Lischka Annette , Doberstein Natalie , Freitag-Wolf Sandra , Koçak Ayla , Gemoll Timo , Heselmeyer-Haddad Kerstin , Ried Thomas , Auer Gert , Habermann Jens K.
Published: April 2023

Test for proportional hazards.
Supplementary Dataset S2 from Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer
Authors: Guan Xiangnan , Sun Duanchen , Lu Eric , Urrutia Joshua A. , Reiter Robert Evan , Rettig Matthew , Evans Christopher P. , Lara Primo , Gleave Martin , Beer Tomasz M. , Thomas George V. , Huang Jiaoti , Aggarwal Rahul R. , Quigley David A. , Foye Adam , Chen William S. , Youngren Jack , Weinstein Alana S. , Stuart Joshua M. , Feng Felix Y. , Small Eric J. , Xia Zheng , Alumkal Joshi J.
Published: April 2023

Supplementary Dataset S2 shows the list of copy number loss genes.
Supplementary Dataset S1 from Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer
Authors: Guan Xiangnan , Sun Duanchen , Lu Eric , Urrutia Joshua A. , Reiter Robert Evan , Rettig Matthew , Evans Christopher P. , Lara Primo , Gleave Martin , Beer Tomasz M. , Thomas George V. , Huang Jiaoti , Aggarwal Rahul R. , Quigley David A. , Foye Adam , Chen William S. , Youngren Jack , Weinstein Alana S. , Stuart Joshua M. , Feng Felix Y. , Small Eric J. , Xia Zheng , Alumkal Joshi J.
Published: April 2023

Supplementary Dataset S1 shows the list of copy number gain genes.
Figure S4 from Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer
Authors: Guan Xiangnan , Sun Duanchen , Lu Eric , Urrutia Joshua A. , Reiter Robert Evan , Rettig Matthew , Evans Christopher P. , Lara Primo , Gleave Martin , Beer Tomasz M. , Thomas George V. , Huang Jiaoti , Aggarwal Rahul R. , Quigley David A. , Foye Adam , Chen William S. , Youngren Jack , Weinstein Alana S. , Stuart Joshua M. , Feng Felix Y. , Small Eric J. , Xia Zheng , Alumkal Joshi J.
Published: April 2023

Figure S4 shows the association of Wnt pathway activation in enzalutamide-resistant samples with 17q22 loss compared with those without loss.
Supplementary Data from Coexpression of IL7 and CCL21 Increases Efficacy of CAR-T Cells in Solid Tumors without Requiring Preconditioned Lymphodepletion
Authors: Luo Hong , Su Jingwen , Sun Ruixin , Sun Yansha , Wang Yi , Dong Yiwei , Shi Bizhi , Jiang Hua , Li Zonghai
Published: April 2023

Supplementary Methods
Supplementary Data from Coexpression of IL7 and CCL21 Increases Efficacy of CAR-T Cells in Solid Tumors without Requiring Preconditioned Lymphodepletion
Authors: Luo Hong , Su Jingwen , Sun Ruixin , Sun Yansha , Wang Yi , Dong Yiwei , Shi Bizhi , Jiang Hua , Li Zonghai
Published: April 2023

Supplementary Results
Supplementary Table ST8 from Radiological Evaluation of Newly Diagnosed Non-Brainstem Pediatric High-Grade Glioma in the HERBY Phase II Trial
Authors: Rodriguez Gutierrez Daniel , Jones Chris , Varlet Pascale , Mackay Alan , Warren Daniel , Warmuth-Metz Monika , Aliaga Esther Sánchez , Calmon Raphael , Hargrave Darren R. , Cañete Adela , Massimino Maura , Azizi Amedeo A. , Le Deley Marie-Cécile , Saran Frank , Rousseau Raphael F. , Zahlmann Gudrun , Garcia Josep , Vassal Gilles , Grill Jacques , Morgan Paul S. , Jaspan Tim
Published: April 2023

Outcome related to location - Midline
Supplementary Table ST7 from Radiological Evaluation of Newly Diagnosed Non-Brainstem Pediatric High-Grade Glioma in the HERBY Phase II Trial
Authors: Rodriguez Gutierrez Daniel , Jones Chris , Varlet Pascale , Mackay Alan , Warren Daniel , Warmuth-Metz Monika , Aliaga Esther Sánchez , Calmon Raphael , Hargrave Darren R. , Cañete Adela , Massimino Maura , Azizi Amedeo A. , Le Deley Marie-Cécile , Saran Frank , Rousseau Raphael F. , Zahlmann Gudrun , Garcia Josep , Vassal Gilles , Grill Jacques , Morgan Paul S. , Jaspan Tim
Published: April 2023

Outcome related to location - Cerebral
Supplementary Table ST5 from Radiological Evaluation of Newly Diagnosed Non-Brainstem Pediatric High-Grade Glioma in the HERBY Phase II Trial
Authors: Rodriguez Gutierrez Daniel , Jones Chris , Varlet Pascale , Mackay Alan , Warren Daniel , Warmuth-Metz Monika , Aliaga Esther Sánchez , Calmon Raphael , Hargrave Darren R. , Cañete Adela , Massimino Maura , Azizi Amedeo A. , Le Deley Marie-Cécile , Saran Frank , Rousseau Raphael F. , Zahlmann Gudrun , Garcia Josep , Vassal Gilles , Grill Jacques , Morgan Paul S. , Jaspan Tim
Published: April 2023

Leptomeningeal metastatic (LMM) dissemination
Supplementary Data from Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia
Authors: Sweet Kendra , Komrokji Rami , Padron Eric , Cubitt Christopher L. , Turner Joel G. , Zhou Junmin , List Alan F. , Sallman David A. , Dawson Jana L. , Sullivan Daniel M. , Chavez Julio , Shah Bijal D. , Lancet Jeffrey E.
Published: April 2023

Supplementary table and figures.
Supplementary Table ST10 from Radiological Evaluation of Newly Diagnosed Non-Brainstem Pediatric High-Grade Glioma in the HERBY Phase II Trial
Authors: Rodriguez Gutierrez Daniel , Jones Chris , Varlet Pascale , Mackay Alan , Warren Daniel , Warmuth-Metz Monika , Aliaga Esther Sánchez , Calmon Raphael , Hargrave Darren R. , Cañete Adela , Massimino Maura , Azizi Amedeo A. , Le Deley Marie-Cécile , Saran Frank , Rousseau Raphael F. , Zahlmann Gudrun , Garcia Josep , Vassal Gilles , Grill Jacques , Morgan Paul S. , Jaspan Tim
Published: April 2023

Outcome measures related to location and major mutation groups for patients with leptomeningeal dissemination (LMM)
Figure S2 from Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors
Authors: Glisson Bonnie S. , Leidner Rom S. , Ferris Robert L. , Powderly John , Rizvi Naiyer A. , Keam Bhumsuk , Schneider Reva , Goel Sanjay , Ohr James P. , Burton Jennifer , Zheng Yanan , Eck Steven , Gribbin Matthew , Streicher Katie , Townsley Danielle M. , Patel Sandip Pravin
Published: April 2023

Figure S2: Concentration-time profiles by ADA status
Supplementary Figure S2 from A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer
Authors: Tolaney Sara M. , Sahebjam Solmaz , Le Rhun Emilie , Bachelot Thomas , Kabos Peter , Awada Ahmad , Yardley Denise , Chan Arlene , Conte Pierfranco , Diéras Véronique , Lin Nancy U. , Bear Melissa , Chapman Sonya C. , Yang Zhengyu , Chen Yanyun , Anders Carey K.
Published: April 2023

Change in parenchymal intracranial (Panel A1) and extracranial (Panel B) tumor size and best overall response, and duration of exposure to abemaciclib (Panel C) in cohort C (HR+, HER2- and HR+, HER2+ MBC with LM). 1Panel A is only for patients with HR+, HER2- MBC with LM, as the patients with HR+, HER2+ MBC had no intracranial parenchymal lesions or post-baseline scans. Note: Patients who did not have an intracranial or extracranial lesion or a post-baseline scan are not shown on waterfall plots. oIndicates patient received prior whole brain radiotherapy. +Indicates patient received prior stereotactic radiosurgery. #Indicates patient received concomitant endocrine therapy. Abbreviations: CR, complete response; HER2+/â^', human epidermal growth factor receptor-2 positive/negative; HR+, hormone receptor positive; MBC, metastatic breast cancer; LM, leptomeningeal metastases; NE, not estimable; PD, progressive disease; PR, partial response; SD, stable disease.
Supplementary Fig 1 from PD-L1 Protein Expression on Both Tumor Cells and Macrophages are Associated with Response to Neoadjuvant Durvalumab with Chemotherapy in Triple-negative Breast Cancer
Authors: Ahmed Fahad Shabbir , Gaule Patricia , McGuire John , Patel Katir , Blenman Kim , Pusztai Lajos , Rimm David L.
Published: April 2023

Ultimapper schematic and images
Supplementary Table 3 from CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial
Authors: You Benoit , Robelin Patrick , Tod Michel , Louvet Christophe , Lotz Jean-Pierre , Abadie-Lacourtoisie Sophie , Fabbro Michel , Desauw Christophe , Bonichon-Lamichhane Nathalie , Kurtz Jean-Emmanuel , Follana Philippe , Leheurteur Marianne , Piano Francesco Del , Ferron Gwénael , De Rauglaudre Gaëtan , Ray-Coquard Isabelle , Combe Pierre , Chevalier-Place Annick , Joly Florence , Leary Alexandra , Pujade-Lauraine Eric , Freyer Gilles , Colomban Olivier
Published: April 2023

Suppl Table 3
Supplementary Data fig 6 from PD-L1 Protein Expression on Both Tumor Cells and Macrophages are Associated with Response to Neoadjuvant Durvalumab with Chemotherapy in Triple-negative Breast Cancer
Authors: Ahmed Fahad Shabbir , Gaule Patricia , McGuire John , Patel Katir , Blenman Kim , Pusztai Lajos , Rimm David L.
Published: April 2023

Univariate and multivariate analysis
Supplementary Table 1 from CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial
Authors: You Benoit , Robelin Patrick , Tod Michel , Louvet Christophe , Lotz Jean-Pierre , Abadie-Lacourtoisie Sophie , Fabbro Michel , Desauw Christophe , Bonichon-Lamichhane Nathalie , Kurtz Jean-Emmanuel , Follana Philippe , Leheurteur Marianne , Piano Francesco Del , Ferron Gwénael , De Rauglaudre Gaëtan , Ray-Coquard Isabelle , Combe Pierre , Chevalier-Place Annick , Joly Florence , Leary Alexandra , Pujade-Lauraine Eric , Freyer Gilles , Colomban Olivier
Published: April 2023

Supplementary Table 1
Supplementary Figure 8 from CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial
Authors: You Benoit , Robelin Patrick , Tod Michel , Louvet Christophe , Lotz Jean-Pierre , Abadie-Lacourtoisie Sophie , Fabbro Michel , Desauw Christophe , Bonichon-Lamichhane Nathalie , Kurtz Jean-Emmanuel , Follana Philippe , Leheurteur Marianne , Piano Francesco Del , Ferron Gwénael , De Rauglaudre Gaëtan , Ray-Coquard Isabelle , Combe Pierre , Chevalier-Place Annick , Joly Florence , Leary Alexandra , Pujade-Lauraine Eric , Freyer Gilles , Colomban Olivier
Published: April 2023

Explorative analyses of progression-free survival according to standardized KELIM terciles (upper vs intermediate + lower) and disease-risk groups, adjusted from Oza et al. Med.: Median; std: standardized; NR: not reached; 95% CI: 95% confidence interval; P: Log-rank test.
Supplementary Figure 2 from Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers
Authors: Høgdall Dan , O'Rourke Colm J. , Dehlendorff Christian , Larsen Ole F. , Jensen Lars H. , Johansen Astrid Z. , Dang Hien , Factor Valentina M. , Grunnet Mie , Mau-Sørensen Morten , Oliveira Douglas V.N.P. , Linnemann Dorte , Boisen Mogens K. , Wang Xin W. , Johansen Julia S. , Andersen Jesper B.
Published: April 2023

Supplementary Figure 2: Correlation of circulating biomarkers with CRP.
Supplementary Figure 6 from CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial
Authors: You Benoit , Robelin Patrick , Tod Michel , Louvet Christophe , Lotz Jean-Pierre , Abadie-Lacourtoisie Sophie , Fabbro Michel , Desauw Christophe , Bonichon-Lamichhane Nathalie , Kurtz Jean-Emmanuel , Follana Philippe , Leheurteur Marianne , Piano Francesco Del , Ferron Gwénael , De Rauglaudre Gaëtan , Ray-Coquard Isabelle , Combe Pierre , Chevalier-Place Annick , Joly Florence , Leary Alexandra , Pujade-Lauraine Eric , Freyer Gilles , Colomban Olivier
Published: April 2023

Explorative analyses of progression-free survival according to standardized KELIM terciles (upper vs intermediate + lower) and completeness of interval debulking surgery. Med.: Median; std: standardized; IDS: interval debulking surgery; NR: not reached; 95% CI: 95% confidence interval; P: Log-rank test.
Supplementary Figure 1 from Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers
Authors: Høgdall Dan , O'Rourke Colm J. , Dehlendorff Christian , Larsen Ole F. , Jensen Lars H. , Johansen Astrid Z. , Dang Hien , Factor Valentina M. , Grunnet Mie , Mau-Sørensen Morten , Oliveira Douglas V.N.P. , Linnemann Dorte , Boisen Mogens K. , Wang Xin W. , Johansen Julia S. , Andersen Jesper B.
Published: April 2023

Supplementary Figure 1: Kaplan-Meier plots depicting progression free survival (PFS) for patients with advanced biliary tract cancer as a function of pretreatment biomarker levels divided into tertiles:
Supplementary Table from Functional Categorization of BRCA1 Variants of Uncertain Clinical Significance in Homologous Recombination Repair Complementation Assays
Authors: Bouwman Peter , van der Heijden Ingrid , van der Gulden Hanneke , de Bruijn Roebi , Braspenning Merel E. , Moghadasi Setareh , Wessels Lodewyk F.A. , Vreeswijk Maaike P.G. , Jonkers Jos
Published: April 2023

Supplementary Table from Functional Categorization of BRCA1 Variants of Uncertain Clinical Significance in Homologous Recombination Repair Complementation Assays
Figure S1 Full Protocol from Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis
Authors: Fader Amanda N. , Roque Dana M. , Siegel Eric , Buza Natalia , Hui Pei , Abdelghany Osama , Chambers Setsuko , Secord Angeles Alvarez , Havrilesky Laura , O'Malley David M. , Backes Floor J. , Nevadunsky Nicole , Edraki Babak , Pikaart Dirk , Lowery William , ElSahwi Karim , Celano Paul , Bellone Stefania , Azodi Masoud , Litkouhi Babak , Ratner Elena , Silasi Dan-Arin , Schwartz Peter E. , Santin Alessandro D.
Published: April 2023

Full Protocol
Supplementary Legend from Multiplexed Evaluation of Microdosed Antineoplastic Agents In Situ in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma
Authors: Gundle Kenneth R. , Deutsch Gary B. , Goodman Howard J. , Pollack Seth M. , Thompson Matthew J. , Davis Jessica L. , Lee Mee-Young , Ramirez Daniel C. , Kerwin William , Bertout Jessica A. , Grenley Marc O. , Sottero Kimberly H.W. , Beirne Emily , Frazier Jason , Dey Joyoti , Ellison Micah , Klinghoffer Richard A. , Maki Robert G.
Published: April 2023

Supplementary Legend
Supplementary Tables from Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer
Authors: Hammer Stefanie , Hagemann Urs B. , Zitzmann-Kolbe Sabine , Larsen Aasmund , Ellingsen Christine , Geraudie Solene , Grant Derek , Indrevoll Baard , Smeets Roger , von Ahsen Oliver , Kristian Alexander , Lejeune Pascale , Hennekes Hartwig , Karlsson Jenny , Bjerke Roger M. , Ryan Olav B. , Cuthbertson Alan S. , Mumberg Dominik
Published: April 2023

Supplementary Table 1
Supplemental Table 1 from Multiplexed Evaluation of Microdosed Antineoplastic Agents In Situ in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma
Authors: Gundle Kenneth R. , Deutsch Gary B. , Goodman Howard J. , Pollack Seth M. , Thompson Matthew J. , Davis Jessica L. , Lee Mee-Young , Ramirez Daniel C. , Kerwin William , Bertout Jessica A. , Grenley Marc O. , Sottero Kimberly H.W. , Beirne Emily , Frazier Jason , Dey Joyoti , Ellison Micah , Klinghoffer Richard A. , Maki Robert G.
Published: April 2023

Table of microinjected drugs
FigureS3 from T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer
Authors: Obradovic Aleksandar Z. , Dallos Matthew C. , Zahurak Marianna L. , Partin Alan W. , Schaeffer Edward M. , Ross Ashley E. , Allaf Mohamad E. , Nirschl Thomas R. , Liu David , Chapman Carolyn G. , O'Neal Tanya , Cao Haiyi , Durham Jennifer N. , Guner Gunes , Baena-Del Valle Javier A. , Ertunc Onur , De Marzo Angelo M. , Antonarakis Emmanuel S. , Drake Charles G.
Published: April 2023

Figure S3
Supplemental Figure 4 from Multiplexed Evaluation of Microdosed Antineoplastic Agents In Situ in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma
Authors: Gundle Kenneth R. , Deutsch Gary B. , Goodman Howard J. , Pollack Seth M. , Thompson Matthew J. , Davis Jessica L. , Lee Mee-Young , Ramirez Daniel C. , Kerwin William , Bertout Jessica A. , Grenley Marc O. , Sottero Kimberly H.W. , Beirne Emily , Frazier Jason , Dey Joyoti , Ellison Micah , Klinghoffer Richard A. , Maki Robert G.
Published: April 2023

Increased phosphorylation of PDGFRï�¡ and downstream effectors in an undifferentiated pleomorphic sarcoma displaying a lack of apoptotic response to microdosed doxorubicin.
Table S2 from A Four-Chemokine Signature Is Associated with a T-cell–Inflamed Phenotype in Primary and Metastatic Pancreatic Cancer
Authors: Romero Joan M. , Grünwald Barbara , Jang Gun-Ho , Bavi Prashant P. , Jhaveri Aaditeya , Masoomian Mehdi , Fischer Sandra E. , Zhang Amy , Denroche Robert E. , Lungu Ilinca M. , De Luca Angela , Bartlett John M.S. , Xu Jing , Li Niandong , Dhaliwal Sharon , Liang Sheng-Ben , Chadwick Dianne , Vyas Foram , Bronsert Peter , Khokha Rama , McGaha Tracy L. , Notta Faiyaz , Ohashi Pamela S. , Done Susan J. , O'Kane Grainne M. , Wilson Julie M. , Knox Jennifer J. , Connor Ashton , Wang Yifan , Zogopoulos George , Gallinger Steven
Published: April 2023

Supplementary Table 2: Top 100 upregulated genes in 4-chemokinehi and 4-chemokinelo patients
Figure S6 from A Four-Chemokine Signature Is Associated with a T-cell–Inflamed Phenotype in Primary and Metastatic Pancreatic Cancer
Authors: Romero Joan M. , Grünwald Barbara , Jang Gun-Ho , Bavi Prashant P. , Jhaveri Aaditeya , Masoomian Mehdi , Fischer Sandra E. , Zhang Amy , Denroche Robert E. , Lungu Ilinca M. , De Luca Angela , Bartlett John M.S. , Xu Jing , Li Niandong , Dhaliwal Sharon , Liang Sheng-Ben , Chadwick Dianne , Vyas Foram , Bronsert Peter , Khokha Rama , McGaha Tracy L. , Notta Faiyaz , Ohashi Pamela S. , Done Susan J. , O'Kane Grainne M. , Wilson Julie M. , Knox Jennifer J. , Connor Ashton , Wang Yifan , Zogopoulos George , Gallinger Steven
Published: April 2023

Supplementary Figure 6: Immune phenotypes were not impacted by cellularity in metastases
Supplementary Table 1, Supplementary Table 2 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma
Authors: Janku Filip , Park Haeseong , Call S. Greg , Madwani Kiran , Oki Yasuhiro , Subbiah Vivek , Hong David S. , Naing Aung , Velez-Bravo Vivianne M. , Barnes Tamara G. , Hagemeister Fredrick B. , Falchook Gerald S. , Karp Daniel D. , Wheler Jennifer J. , Piha-Paul Sarina A. , Garrido-Laguna Ignacio , Shpall Elizabeth J. , Fayad Luis E. , Neelapu Sattva S. , Meric-Bernstam Funda , Kurzrock Razelle , Fanale Michelle A.
Published: April 2023

Supplementary Table 1. Durations of dose interruptions in vorinostat and sirolimus arm; Supplementary Table 2. Durations of dose interruptions in vorinostat and everolimus arm
Figure S2 from A Four-Chemokine Signature Is Associated with a T-cell–Inflamed Phenotype in Primary and Metastatic Pancreatic Cancer
Authors: Romero Joan M. , Grünwald Barbara , Jang Gun-Ho , Bavi Prashant P. , Jhaveri Aaditeya , Masoomian Mehdi , Fischer Sandra E. , Zhang Amy , Denroche Robert E. , Lungu Ilinca M. , De Luca Angela , Bartlett John M.S. , Xu Jing , Li Niandong , Dhaliwal Sharon , Liang Sheng-Ben , Chadwick Dianne , Vyas Foram , Bronsert Peter , Khokha Rama , McGaha Tracy L. , Notta Faiyaz , Ohashi Pamela S. , Done Susan J. , O'Kane Grainne M. , Wilson Julie M. , Knox Jennifer J. , Connor Ashton , Wang Yifan , Zogopoulos George , Gallinger Steven
Published: April 2023

Supplementary Figure 2: Transcriptomic subtypes versus 4-chemokinehi and 4-chemokinelo in both primary and metastatic tumours
Supplementary Figure 4 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma
Authors: Janku Filip , Park Haeseong , Call S. Greg , Madwani Kiran , Oki Yasuhiro , Subbiah Vivek , Hong David S. , Naing Aung , Velez-Bravo Vivianne M. , Barnes Tamara G. , Hagemeister Fredrick B. , Falchook Gerald S. , Karp Daniel D. , Wheler Jennifer J. , Piha-Paul Sarina A. , Garrido-Laguna Ignacio , Shpall Elizabeth J. , Fayad Luis E. , Neelapu Sattva S. , Meric-Bernstam Funda , Kurzrock Razelle , Fanale Michelle A.
Published: April 2023

In patients treated with vorinostat and sirolimus, there was a trend towards a longer median progression-free survival in patients with ECOG performance status 0 compared to ECOG 1 or 2 (not reached vs. 4.6 months, 95% CI 1.5-7.7; P = 0.06).
Table S4 from Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer
Authors: Allott Emma H. , Ebot Ericka M. , Stopsack Konrad H. , Gonzalez-Feliciano Amparo G. , Markt Sarah C. , Wilson Kathryn M. , Ahearn Thomas U. , Gerke Travis A. , Downer Mary K. , Rider Jennifer R. , Freedland Stephen J. , Lotan Tamara L. , Kantoff Philip W. , Platz Elizabeth A. , Loda Massimo , Stampfer Meir J. , Giovannucci Edward , Sweeney Christopher J. , Finn Stephen P. , Mucci Lorelei A.
Published: April 2023

Age-adjusted gene set enrichment analysis showing the top ten gene sets upregulated and downregulated in tumor-adjacent normal prostate tissue of ever (n=10) versus never (n=103) statin users, ordered by the normalized enrichment score
Table S3 from Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer
Authors: Allott Emma H. , Ebot Ericka M. , Stopsack Konrad H. , Gonzalez-Feliciano Amparo G. , Markt Sarah C. , Wilson Kathryn M. , Ahearn Thomas U. , Gerke Travis A. , Downer Mary K. , Rider Jennifer R. , Freedland Stephen J. , Lotan Tamara L. , Kantoff Philip W. , Platz Elizabeth A. , Loda Massimo , Stampfer Meir J. , Giovannucci Edward , Sweeney Christopher J. , Finn Stephen P. , Mucci Lorelei A.
Published: April 2023

Hazard ratios and 95% confidence intervals of the association between statin use and risk of prostate cancer subgroups classified by ERG and PTEN status
Figure S2 from Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma
Authors: Algazi Alain P. , Twitty Christopher G. , Tsai Katy K. , Le Mai , Pierce Robert , Browning Erica , Hermiz Reneta , Canton David A. , Bannavong Donna , Oglesby Arielle , Francisco Murray , Fong Lawrence , Pittet Mikael J. , Arlauckas Sean P. , Garris Christopher , Levine Lauren P. , Bifulco Carlos , Ballesteros-Merino Carmen , Bhatia Shailender , Gargosky Sharron , Andtbacka Robert H.I. , Fox Bernard A. , Rosenblum Michael D. , Daud Adil I.
Published: April 2023

Treatment related changes in cell type scores
Figure S7 from Surfactant Expression Defines an Inflamed Subtype of Lung Adenocarcinoma Brain Metastases that Correlates with Prolonged Survival
Authors: Pocha Kolja , Mock Andreas , Rapp Carmen , Dettling Steffen , Warta Rolf , Geisenberger Christoph , Jungk Christine , Martins Leila R. , Grabe Niels , Reuss David , Debus Juergen , von Deimling Andreas , Abdollahi Amir , Unterberg Andreas , Herold-Mende Christel C.
Published: April 2023

DNA methylation analysis in primary TCGA LUADs and comparative analysis of methylation of all CpG sites in the primary and metastatic tumors.
Figure S1 from Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma
Authors: Algazi Alain P. , Twitty Christopher G. , Tsai Katy K. , Le Mai , Pierce Robert , Browning Erica , Hermiz Reneta , Canton David A. , Bannavong Donna , Oglesby Arielle , Francisco Murray , Fong Lawrence , Pittet Mikael J. , Arlauckas Sean P. , Garris Christopher , Levine Lauren P. , Bifulco Carlos , Ballesteros-Merino Carmen , Bhatia Shailender , Gargosky Sharron , Andtbacka Robert H.I. , Fox Bernard A. , Rosenblum Michael D. , Daud Adil I.
Published: April 2023

IFN-gamma profile
Figure S1 from Surfactant Expression Defines an Inflamed Subtype of Lung Adenocarcinoma Brain Metastases that Correlates with Prolonged Survival
Authors: Pocha Kolja , Mock Andreas , Rapp Carmen , Dettling Steffen , Warta Rolf , Geisenberger Christoph , Jungk Christine , Martins Leila R. , Grabe Niels , Reuss David , Debus Juergen , von Deimling Andreas , Abdollahi Amir , Unterberg Andreas , Herold-Mende Christel C.
Published: April 2023

TissueQuest gating strategy and Kaplan-Meier plots of significant clinical parameters.
Supplemental Table S1 from Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase–Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type
Authors: Ji Jennifer X. , Cochrane Dawn R. , Tessier-Cloutier Basile , Chen Shary Yutin , Ho Germain , Pathak Khyatiben V. , Alcazar Isabel N. , Farnell David , Leung Samuel , Cheng Angela , Chow Christine , Colborne Shane , Negri Gian Luca , Kommoss Friedrich , Karnezis Anthony , Morin Gregg B. , McAlpine Jessica N. , Gilks C. Blake , Weissman Bernard E. , Trent Jeffrey M. , Hoang Lynn , Pirrotte Patrick , Wang Yemin , Huntsman David G.
Published: April 2023

Table containing proteins differentially expressed in at least two rarer ovarian cancer subtypes when compared to HGSC.
Supplementary Figure 7 from Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial
Authors: Uppaluri Ravindra , Campbell Katie M. , Egloff Ann Marie , Zolkind Paul , Skidmore Zachary L. , Nussenbaum Brian , Paniello Randal C. , Rich Jason T. , Jackson Ryan , Pipkorn Patrik , Michel Loren S. , Ley Jessica , Oppelt Peter , Dunn Gavin P. , Barnell Erica K. , Spies Nicholas C. , Lin Tianxiang , Li Tiantian , Mulder David T. , Hanna Youstina , Cirlan Iulia , Pugh Trevor J. , Mudianto Tenny , Riley Rachel , Zhou Liye , Jo Vickie Y. , Stachler Matthew D. , Hanna Glenn J. , Kass Jason , Haddad Robert , Schoenfeld Jonathan D. , Gjini Evisa , Lako Ana , Thorstad Wade , Gay Hiram A. , Daly Mackenzie , Rodig Scott J. , Hagemann Ian S. , Kallogjeri Dorina , Piccirillo Jay F. , Chernock Rebecca D. , Griffith Malachi , Griffith Obi L. , Adkins Douglas R.
Published: April 2023

Supplementary Figure
Figure S7 from Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase–Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type
Authors: Ji Jennifer X. , Cochrane Dawn R. , Tessier-Cloutier Basile , Chen Shary Yutin , Ho Germain , Pathak Khyatiben V. , Alcazar Isabel N. , Farnell David , Leung Samuel , Cheng Angela , Chow Christine , Colborne Shane , Negri Gian Luca , Kommoss Friedrich , Karnezis Anthony , Morin Gregg B. , McAlpine Jessica N. , Gilks C. Blake , Weissman Bernard E. , Trent Jeffrey M. , Hoang Lynn , Pirrotte Patrick , Wang Yemin , Huntsman David G.
Published: April 2023

Mouse models of SCCOHT cell lines. A, Representative histology of kidney and liver from COV434-implanted mouse in the control group, and in the 30mg/kg ADI-PEG20 group which exhibited abnormal organs upon macroscopic examination at necropsy. B, BRG1 IHC for the masses above the heart found in 2 mice in the treatment groups. Top image: mass only (mouse DGH12-2-14); bottom image, mass adjacent to normal heart (mouse DGH12-2-15). C, tumor volume and weight of SCCOHT1 mouse model. Significance was calculated using ANOVA, followed by a post-hoc Tukey's test. Error bars represent standard error of mean. D, ASS1 re-expression in SCCOHT1 cells in both saline control group and 30mg/kg treated groups. E, Representative tunnel assay images from each treatment group indicating no significant increase in apoptosis in tumors from the ADI-PEG20 treated compared to saline-treated groups, and F, COV434 subcutaneous xenograft showing foci of ASS1 re-expression in treated groups. G, average mouse weight of each mouse model, and H, plots reflecting the tumour weight adjusted by mouse weight (tumour weight/mouse weight).
Supplementary Figure 6 from Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial
Authors: Uppaluri Ravindra , Campbell Katie M. , Egloff Ann Marie , Zolkind Paul , Skidmore Zachary L. , Nussenbaum Brian , Paniello Randal C. , Rich Jason T. , Jackson Ryan , Pipkorn Patrik , Michel Loren S. , Ley Jessica , Oppelt Peter , Dunn Gavin P. , Barnell Erica K. , Spies Nicholas C. , Lin Tianxiang , Li Tiantian , Mulder David T. , Hanna Youstina , Cirlan Iulia , Pugh Trevor J. , Mudianto Tenny , Riley Rachel , Zhou Liye , Jo Vickie Y. , Stachler Matthew D. , Hanna Glenn J. , Kass Jason , Haddad Robert , Schoenfeld Jonathan D. , Gjini Evisa , Lako Ana , Thorstad Wade , Gay Hiram A. , Daly Mackenzie , Rodig Scott J. , Hagemann Ian S. , Kallogjeri Dorina , Piccirillo Jay F. , Chernock Rebecca D. , Griffith Malachi , Griffith Obi L. , Adkins Douglas R.
Published: April 2023

Supplementary Figure
Supplementary Figure 5 from Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial
Authors: Uppaluri Ravindra , Campbell Katie M. , Egloff Ann Marie , Zolkind Paul , Skidmore Zachary L. , Nussenbaum Brian , Paniello Randal C. , Rich Jason T. , Jackson Ryan , Pipkorn Patrik , Michel Loren S. , Ley Jessica , Oppelt Peter , Dunn Gavin P. , Barnell Erica K. , Spies Nicholas C. , Lin Tianxiang , Li Tiantian , Mulder David T. , Hanna Youstina , Cirlan Iulia , Pugh Trevor J. , Mudianto Tenny , Riley Rachel , Zhou Liye , Jo Vickie Y. , Stachler Matthew D. , Hanna Glenn J. , Kass Jason , Haddad Robert , Schoenfeld Jonathan D. , Gjini Evisa , Lako Ana , Thorstad Wade , Gay Hiram A. , Daly Mackenzie , Rodig Scott J. , Hagemann Ian S. , Kallogjeri Dorina , Piccirillo Jay F. , Chernock Rebecca D. , Griffith Malachi , Griffith Obi L. , Adkins Douglas R.
Published: April 2023

Supplementary Figure
Figure S4 from Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase–Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type
Authors: Ji Jennifer X. , Cochrane Dawn R. , Tessier-Cloutier Basile , Chen Shary Yutin , Ho Germain , Pathak Khyatiben V. , Alcazar Isabel N. , Farnell David , Leung Samuel , Cheng Angela , Chow Christine , Colborne Shane , Negri Gian Luca , Kommoss Friedrich , Karnezis Anthony , Morin Gregg B. , McAlpine Jessica N. , Gilks C. Blake , Weissman Bernard E. , Trent Jeffrey M. , Hoang Lynn , Pirrotte Patrick , Wang Yemin , Huntsman David G.
Published: April 2023

ASS1 in ovarian cancer cell lines. A, Re-expression of SMARCA4 does not affect the expression of ASS1. SCCOHT cells were infected with Lenti-GFP or Lenti-SMARCA4 for 24 hours followed by puromycin selection for 72 hours. Cells were then harvested for protein quantification using mass spectrometry. B, ASS1 immunohistochemistry on FFPE cell line pellets showing positivity in JHOC 7 and JHOC 9, and lack of expression in ES2, JHOC 5, and TOV112D. C, ASS1 immunohistochemistry on FFPE cell line pellets for CRISPR knock out (JHOC 7 ASS1 CRISPR A8) and over-expression (JHOC 5 ASS1 CMV) cell lines compared to their corresponding vector controls (JHOC 7 CRISPR NTC30 and JHOC5 vector control, respectively). D, qPCR showing differential ASS1 mRNA expression levels between ovarian cancer cell lines. Difference of relative mRNA expression between cell lines is determined by one-way ANOVA with post-hoc Tukey test. * p<0.05 when compared to JHOC 7; ## p <0.001 when compared to JHOC 9. Error bars represent standard error of mean. E, ASS1 promoter methylation status, all samples were run on the same gel. F, Cell lines are sensitive to depletion of arginine and citrulline from growth media. Addition of citrulline rescued the growth of ASS1 expressing JHOC7, but not the ASS1 deficient JHOC 5 and COV434. -
Supplementary Figure 2 from Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial
Authors: Uppaluri Ravindra , Campbell Katie M. , Egloff Ann Marie , Zolkind Paul , Skidmore Zachary L. , Nussenbaum Brian , Paniello Randal C. , Rich Jason T. , Jackson Ryan , Pipkorn Patrik , Michel Loren S. , Ley Jessica , Oppelt Peter , Dunn Gavin P. , Barnell Erica K. , Spies Nicholas C. , Lin Tianxiang , Li Tiantian , Mulder David T. , Hanna Youstina , Cirlan Iulia , Pugh Trevor J. , Mudianto Tenny , Riley Rachel , Zhou Liye , Jo Vickie Y. , Stachler Matthew D. , Hanna Glenn J. , Kass Jason , Haddad Robert , Schoenfeld Jonathan D. , Gjini Evisa , Lako Ana , Thorstad Wade , Gay Hiram A. , Daly Mackenzie , Rodig Scott J. , Hagemann Ian S. , Kallogjeri Dorina , Piccirillo Jay F. , Chernock Rebecca D. , Griffith Malachi , Griffith Obi L. , Adkins Douglas R.
Published: April 2023

Supplementary Figure
Figure S3 from Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase–Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type
Authors: Ji Jennifer X. , Cochrane Dawn R. , Tessier-Cloutier Basile , Chen Shary Yutin , Ho Germain , Pathak Khyatiben V. , Alcazar Isabel N. , Farnell David , Leung Samuel , Cheng Angela , Chow Christine , Colborne Shane , Negri Gian Luca , Kommoss Friedrich , Karnezis Anthony , Morin Gregg B. , McAlpine Jessica N. , Gilks C. Blake , Weissman Bernard E. , Trent Jeffrey M. , Hoang Lynn , Pirrotte Patrick , Wang Yemin , Huntsman David G.
Published: April 2023

Decreased ASS1 expression correlates with CTNNB1 mutation in ENOC and EEC. A, ASS1 mRNA Z-score in 26 cases of ENOC cases described in publication by Wang et al (30). B, ASS1 histoscore distribution in CTNNB1 mutated and wildtype endometroid endometrial and endometrioid ovarian cancers. C, ASS1 mRNA raw counts in the TCGA endometrial cohort as related to CTNNB1 mutation status. P values were calculated using a Wilcoxin rank sum test.